Twist Bioscience Corporation $TWST Stock: Pictet Asset Management Holding SA Decreases Position

Pictet Asset Management Holding SA trimmed its stake in Twist Bioscience Corporation (NASDAQ:TWST) by 23.3% during the third quarter, Holdings Channel reports. The fund owned 83,061 shares of the company’s stock after selling 25,206 shares during the period. Pictet Asset Management Holding SA’s holdings in Twist Bioscience were worth $15,523,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also bought and sold shares of the company. BlackRock Inc. bought a new position in shares of Twist Bioscience during the 2nd quarter worth $600,191,000. William Blair Investment Management LLC purchased a new stake in shares of Twist Bioscience during the second quarter worth $223,722,000. Bank of America Corp DE bought a new position in shares of Twist Bioscience in the second quarter worth $94,922,000. Allspring Global Investments Holdings LLC bought a new stake in shares of Twist Bioscience during the 1st quarter valued at $22,563,000. Finally, Sei Investments Co. increased its position in shares of Twist Bioscience by 31.2% during the first quarter. Sei Investments Co. now owns 354,420 shares of the company’s stock valued at $16,842,000 after buying an additional 84,321 shares during the period.

Insiders Place Their Bets

In other news, SVP Paula Green sold 10,088 shares of the firm’s stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $188.88, for a total value of $1,905,421.44. Following the completion of the sale, the senior vice president directly owned 106,632 shares of the company’s stock, valued at approximately $20,140,652.16. This trade represents a 8.64% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Emily Leproust sold 356,546 shares of the stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $157.99, for a total transaction of $56,330,702.54. Following the completion of the transaction, the chief executive officer directly owned 620,589 shares of the company’s stock, valued at approximately $98,046,856.11. The trade was a 36.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 495,279 shares of company stock worth $80,489,387 in the last quarter. 3.08% of the stock is currently owned by company insiders.

Twist Bioscience Stock Down 6.8%

TWST opened at $114.22 on Friday. Twist Bioscience Corporation has a 12 month low of $23.30 and a 12 month high of $219.71. The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03. The business’s 50-day moving average price is $150.57 and its 200-day moving average price is $92.73. The company has a market cap of $7.16 billion, a P/E ratio of -51.45 and a beta of 2.25.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.07. Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%. The business had revenue of $126.64 million for the quarter, compared to analysts’ expectations of $123.55 million. The firm’s revenue for the quarter was up 26.7% compared to the same quarter last year. On average, equities analysts expect that Twist Bioscience Corporation will post -2.11 EPS for the current year.

Twist Bioscience News Summary

Investors following TWST have been watching these news items:

• Positive Sentiment: Fiscal 2027 first-quarter revenue guidance of $130 million–$132 million topped the $126.3 million consensus estimate, indicating continued near-term growth. Article: Twist Bioscience Earnings and Guidance
• Positive Sentiment: AI drug discovery generated $59.1 million in fiscal 2026, highlighting a growing business area for the company. Article: Twist Bioscience: 3 Key Takeaways for Long-Term Investors
• Negative Sentiment: Fiscal 2027 revenue guidance of $550 million–$560 million was only slightly above the $549 million consensus. Reports characterized the outlook as insufficient to satisfy investors, helping explain why the stock fell despite the quarterly beats. Article: Twist Bio Slips Despite Q4 Beat After Underwhelming FY27 Outlook

Analyst Ratings Changes

TWST has been the subject of a number of recent analyst reports. Canaccord Genuity Group boosted their price target on shares of Twist Bioscience from $120.00 to $205.00 and gave the company a “buy” rating in a research report on Monday, October 12th. Barclays lifted their price target on Twist Bioscience from $112.00 to $215.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, September 21st. UBS Group assumed coverage on shares of Twist Bioscience in a report on Wednesday, September 9th. They issued a “neutral” rating and a $144.00 price target on the stock. Finally, Piper Sandler lifted their price objective on shares of Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a report on Wednesday, August 5th. Seven equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Twist Bioscience currently has a consensus rating of “Hold” and an average price target of $153.00.

Twist Bioscience Profile

Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications. The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.